Startseite Kongressberichte & Archiv Archiv 2020 ASCO20 Virtual Scientific Meeting Oral Sessions Breast Cancer II

Breast Cancer — Metastatic

Oncoletter provides you with the abstract's links. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

1000 KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortes, David W. Cescon, Hope S. Rugo, et al.
 
 
 
(Interview zur Studie mit Michael Untch, Berlin-Buch)
 
Watch also the ecancer interview with Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------

1001 Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
 
Priyanka Sharma, Eve Rodler, William E. Barlow, et al. 
 
The abstract concludes:
Clinical trial information: NCT02595905.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1002 TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
 
Nadine M. Tung, Mark E. Robson, Steffen Ventz, et al. (Interview zur Studie mit Wolfgang Janni, Ulm)
 
Clinical trial information: NCT03344965.

---------------------------------------------------------------------------------------------------------------------------------------------------------

1003 Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.
 
Binghe Xu, Min Yan, Fei Ma, et al. 
 
Clinical trial information: NCT03080805.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1005 Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
 
Nancy U. Lin, Rashmi Krishna Murthy, Carey K. Anders, Vet al. (Interview zum Thema mit Nadia Harbeck, München)
  
Clinical trial information: NCT02614794.
 
See the report in the ASCO DAILY NEWS: 

Triplet Combination Considered New Standard of Care for Patients With HER2-Positive Metastatic Breast Cancer, Brain Metastases

--------------------------------------------------------------------------------------------------------------------------------------------------------

1006 Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.
 
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, et al.  (Interview zum Thema mit Christian Jackisch, Offenbach)
 
Clinical trial information: NCT03056755.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:

--------------------------------------------------------------------------------------------------------------------------------------------------------

1007 PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2­ metastatic breast cancer.
 
Antonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al. (Interview zum Thema mit Christian Jackisch, Offenbach)
 
Clinical trial information: NCT02491983.

--------------------------------------------------------------------------------------------------------------------------------------------------------

1008 Randomized trial of a collaborative palliative and oncology care intervention to improve communication about end-of-life care in patients with metastatic breast cancer.
 
Jennifer S. Temel, Beverly Moy, Areej El-Jawahri, et al. (Interview zum Thema mit Volkmar Müller, Hamburg)
 
 

--------------------------------------------------------------------------------------------------------------------------------------------------------

Poster Session:

1055 Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).

Michelino De Laurentiis, Simona Borstnar, Mario Campone, et al.

Clinical trial information: NCT02941926.

CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
view slide set

--------------------------------------------------------------------------------------------------------------------------------------------------------

MORE ABSTRACTS:

Clinical Science Symposium
Steps Forward and Lessons Learned: Using Biomarkers to Guide Targeted Therapies in Breast Cancer, The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium supported by the Breast Cancer Research Foundation®.
 
Poster Discussion Session
Breast Cancer—Metastatic
 
Poster Session
Breast Cancer—Metastatic
 
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Breast (Abstracts #LBA2, 501, 506, 1000, 1002, 1007)
Access Content Now